Compositions and methods for treating chronic myelomonocytic leukemia
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorEric Padron
Life of this patent
Estimating the term…
Abstract
As disclosed herein, the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is overexpressed and prognostic in Chronic Myelomonocytic Leukemia (CMML). MALAT1 depletion is disclosed herein as therapeutic strategy for treating CMML and other MALAT1 overexpressing leukemias. Also disclosed herein is a method of treating a subject with a leukemia that involves co-administering to the subject a MALAT1 silencing agent and a therapeutically effective amount of a differentiation agent, such as all-trans retinoic acid (ATRA).
Claims12
A method for treating a leukemia in a subject, comprising administering to the subject a MALAT1 silencing agent and a therapeutically effective amount of retinoic acid.
A composition, comprising a therapeutically effective amount of a MALAT1 silencing agent and a therapeutically effective amount of retinoic acid.
Dependencies are inferred from the claim text.